-
NM-CRPC patients in the treatment of testosterone elevated, fatigue discomfort, one trick to fix! Classic cases.
Time of Update: 2020-07-19
from the real world cases, we can see that after the first-line treatment of apartamide, the PSA of nm-crpc patients continued to decline, the testosterone dropped to the lowest level in history, and the physical and mental state improved significantly.
-
The world's first clinical study results come out: the Ochitinib drug resistance dilemma caused by the triple-shun mutation is expected to be solved.
Time of Update: 2020-07-19
the published data of patients with triple CIS mutation treated with bugatinib and cetuximab is the first clinical study compared with chemotherapy in the world.
-
Skin Squamous Cell Carcinoma (cSCC) immunotherapy! Mercado anti-PD-1 therapy Keytruda (Corrida) new indications approved by the U.S. FDA!
Time of Update: 2020-07-19
, June 25, 2020 /PRNewswire Biovalley BIOON/-- Merck and Co recently announced that the U.S Food and Drug Administration ( FDA ) has approved the anti-PD-1 therapy Keytruda (Corrida, generic name:
-
Nature: Interleukin-18 or become a new immune hot spot! Yale scientists have broken through the "bait receptors" secreted by cancer cells and found promising new immune checkpoints. Scientific discoveries.
Time of Update: 2020-07-19
Their latest paper published in nature pointed out that the reason why IL-18 failed to play an anti-tumor role was that after it entered the body, cancer cells would secrete a large number of IL-18BP, the receptor of IL-18, which competitively binds to IL-18, and snatched away the immune promoting effect that IL-18 should have played!
-
Expert review: Clinical trials have shown that fasting can aid breast cancer treatment, enhance the effect severity of chemotherapy, reduce side effects.
Time of Update: 2020-07-19
expert comments: Miao Changhong (director of anesthesia department, Zhongshan Hospital Affiliated to Fudan University), this is the first randomized controlled study to evaluate the side effects and chemotherapy efficacy of simulated restricted diet on cancer patients.
-
The Lancet sub-issue: a new breakthrough in combined immunotherapy for stomach cancer! Paboli-Zhumonodini-lunvastini's immune combined anti-vascular program, the objective mitigation rate of first- and second-line treatment was 69%. Clinical discovery.
Time of Update: 2020-07-19
In the treatment of gastric cancer, pabolizumab has failed: in the second-line treatment of phase III keynote-061 trial, it did not show advantages over paclitaxel chemotherapy; in the first-line treatment of keynote-062 test, pabolizumab combined with chemotherapy was not as good as monotherapy, and the benefit of single drug was limited to patients with PD-L1 CPS ≥ 10 [2-3].
-
Professor Chen Mingyuan's team innovation: nasal endoscopy minimally invasive surgical technology to treat the initial treatment of early nasopharyngeal cancer.
Time of Update: 2020-07-19
previous studies have shown that minimally invasive surgery has a significantly higher 5-year overall survival rate than intensity-modulated radiation therapy for locally recurrent nasopharyngeal carcinoma, with fewer treatment-related side effects and lower medical costs.
-
Nature Sub-journal: Challenging classic, multi-low-dose drug combinations are effective in treating non-small cell lung cancer without resistance.
Time of Update: 2020-07-19
although this study is aimed at EGFR mutant non-small cell lung cancer, multiple low-dose (MLD) treatment strategies may also be effective for other types of tumors.
in general, multiple low-dose (MLD) therapy for EGFR mutated non-small cell lung cancer (NSCLC) can effectively inhibit the development of drug resistance without associated toxicity.
-
Cell Sub-Journal: Major Discovery! A metabolic enzyme inhibits the growth and spread of liver cancer cells.
Time of Update: 2020-07-19
recently, a study in the United States found an enzyme that can prevent the rapid growth and proliferation of liver cancer cells, which brings new hope for the treatment of liver cancer in the future.
-
2020 EHA Express-Lymphoma Microclass: Ibtinib can significantly improve the recurrent central nervous system's cell lymphoma remission and survival.
Time of Update: 2020-07-19
I would like to share with you today an abstract of oral published by the 2020 EHA, which compared the efficacy of ibutilib and immunochemotherapy in the treatment of recurrent mantle cell lymphoma (MCL) in the central nervous system.
-
Summary: Take stock of the 2020 single-cell sequencing study - Tumor.
Time of Update: 2020-07-19
1.29 single cell sequencing of CLL treatment: shared gene scheme, personalized implementation of patients by the research team led by the molecular medicine research center of the Austrian Academy of Sciences (CeMM), using single cell sequencing and epigenetic analysis methods to conduct a detailed study on the response to targeted leukemia treatment.
-
One article to master the evaluation of the efficacy of lymphoma.
Time of Update: 2020-07-19
the accurate judgment of the baseline lesions is very important for the follow-up intermediate / end-stage efficacy evaluation of lymphoma patients.
The little assistant will collect valuable content regularly and share it in the medical knowledge source topic circle.
-
Express . . . Preclinical results of anti-PD-1 therapy resistance and regenerative metaCD28 bispecific antibodies were published.
Time of Update: 2020-07-19
Today, regeneron announced that its new bispecific antibody targeting CD28 costimulatory receptor, combined with anti PD-1 antibody, can overcome the resistance of anti PD-1 monotherapy in a variety o
-
Progress in research on tumor-targeted superantigens
Time of Update: 2020-07-19
Immunotherapy is a hot and future trend in the field of cancer research In the process of tumor immunotherapy, the targetspecificness of the drug to tumor tissue and the effectiveness of the drug i
-
Roche introduces automated digital pathology algorithm uPath PD-L1 to improve the speed and accuracy of lung cancer (NSCLC) diagnosis!
Time of Update: 2020-07-19
, June 28, 2020 // Biovalley BIOON/Roche has announced the launch of the EUROPEAN Union's CE-IVD-certified automated digital pathology algorithm, uPath PD-L1 (SP263), for non-small cell lung cancer
-
Large-scale cohort studies have found that highly acidic foods increase the risk of breast cancer recurrence and death in people with a history of smoke.
Time of Update: 2020-07-19
titled "increased acid producing diet and past smoking intensity are associated with worse diagnostics along with breast cancer survivors: a prospective cohort study", the researchers analyzed the dietary patterns of 2950 survivors of early breast cancer, some of whom had smoked in the past and others had never smoked.
-
Strong attack: new immunotherapy and double immunocombination therapy, late-stage solid tumor treatment new direction!
Time of Update: 2020-07-19
this is the first dose escalation study to evaluate the preliminary safety and antitumor activity of tiragolumab combined with atilizumab for advanced solid tumors.
in PD-L1 positive tumors without immunotherapy (including NSCLC), tiragolumab combined with atilizumab showed preliminary antitumor activity.
-
Lung cancer "targeted and immunized"! First AXL kinase inhibitor bemcentinib in conjunction with Keytruda (Coreda) to demonstrate strong efficacy!
Time of Update: 2020-07-19
, 25 June 2020 /PRNewswire / -- BerGenBio is a biopharmaceutical company based in Norway dedicated to the development of new selective AXL kinase inhibitors Recently, the company released positive d
-
3 plus pure health letter: uncovering the single gene mining trap.
Time of Update: 2020-07-19
The authors identified and verified the expression of prkacb in normal tissues and tumor tissues of patients with colorectal cancer by using GEO, oncomine and TCGA databases.
Next, the authors downloaded temporary TCGA data from cbioportal database to analyze the impact of low prkacb expression on the survival rate of patients.
-
Fat can destroy three generations! Obesity in mothers increases the risk of liver cancer in future generations.
Time of Update: 2020-07-19
recently, the Journal of In a new study published in Hepatology, a team led by Professor Zheng Ling, chief researcher of School of life sciences, Wuhan University, and Professor Huang Kun, affiliated Tongji School of pharmacy, Tongji Medical College, Huazhong University of science and technology, found that a microRNA in the mothers of obese mice seemed to be susceptible to liver cancer, thus increasing the possibility of their offspring and offspring suffering from liver cancer.
